Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Wave Life Sciences reports transformative 2022 with promising clinical advancements

Wave Life Sciences showcased strong clinical progress and financial discipline in Q4 2022.
The collaboration with GSK and advancements in RNA editing and RNAi technologies position Wave for future success.
Despite challenges in increased expenses, Wave's focus on innovative therapies and strategic partnerships bode well for their future.

Wave Life Sciences reports Q1 progress, poised for RNA innovation

Wave Life Sciences showcased strong financial performance, significant program advancements, and a leadership position in RNA editing technology during Q1 2023.
The company's strategic shift, collaboration with GSK, and focus on additional endpoints beyond traditional measures highlight their commitment to innovation and patient outcomes.
While facing challenges in study designs and editing efficiency assessments, Wave's opportunities lie in differentiation, partnerships, and further advancements in precision medicine.

Wave Life Sciences advances RNA editing technology and secures key collaborations

Wave Life Sciences showcased strong progress in RNA editing and clinical programs, bolstered by collaborations and financial stability.
While facing challenges in off-target effects and patient selection, Wave aims to demonstrate leadership in protein restoration through RNA editing.
Anticipated milestones from GSK, advancements in AIMer technology, and upcoming trial data offer promising opportunities for Wave's growth.

Wave Life Sciences reports strong Q3 earnings and advances RNA pipeline

Wave Life Sciences demonstrated financial strength with positive net income and a healthy cash position.
The company's focus on RNA medicine pipeline advancement and collaborations with GSK show promise for future growth.
Challenges lie in addressing questions on program development, treatment functionality, and ensuring treatment efficacy and patient compliance.

Wave Life Sciences reports successful 2023, eyes growth in RNA editing and obesity programs

Wave Life Sciences had a successful year in 2023, with promising advancements in key programs and a stable financial position.
The company faces challenges in managing expenses and meeting high expectations for upcoming clinical data readouts.
However, Wave's strengths lie in its innovative RNA editing technology, diversified pipeline, and collaborations for revenue generation.
Opportunities abound in market differentiation, revenue growth, and addressing unmet medical needs through their unique programs.

Wave Life Sciences reports Q1 loss but shows promise in therapies

Wave Life Sciences is making strides in advancing their therapeutic portfolio with promising clinical trial progress and positive preclinical results.
While facing challenges in program validation and expansion, the company's strong R&D efforts and financial stability position them well for future growth.
With upcoming milestones and a focus on innovative therapies, Wave has opportunities to establish itself as a key player in the biopharmaceutical industry.

Wave Life Sciences reports breakthroughs in RNA editing and clinical progress

Wave Life Sciences showcased a successful quarter with advancements in RNA editing and positive clinical trial outcomes, positioning the company for future growth.
While facing financial challenges, the company's strong cash position and promising pipeline present opportunities for sustained innovation and market expansion.
Navigating regulatory pathways for accelerated approvals and leveraging breakthrough technologies underscore Wave's potential for long-term success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 5, 2021, to discuss its second quarter 2021 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021

Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder that may result in lung disease or liver disease.

Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave's pipeline programs, including the first in vivo data from the company's ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD).

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2021 Results - Earnings Call Transcript

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimate of ($0.59).

Recap: WAVE Life Sciences Q1 Earnings

Clinical trials underway with next-generation candidates incorporating PN chemistry

Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer is scheduled to give a presentation at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 4:15 p.m. ET.

Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 13, 2021, to discuss its first quarter 2021 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021

Affimed

Chimerix

Epizyme

Seelos Therapeutics

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential

No one ever said drug development was easy.

Here's Why Wave Life Sciences Crashed Today

The stock price of Wave Life Sciences Ltd (NASDAQ: WVE) fell by over 20% pre-market. This is why it happened.

WVE Stock Price Fell Over 20% Pre-Market: Why It Happened

Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happened: WVE-120102 failed to separate from the placebo with no evidence of a dose-response on mutant Huntingtin protein (mHTT) at any of the doses.

Wave Life Sciences Stock Plunges After Antisense Oligonucleotide Candidates Disappoint In Huntington's Disease Study

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?

CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer and Michael Panzara, MD, MPH, Chief Medical Officer and Head of Therapeutics Discovery and Development are scheduled to participate virtually in an analyst-led fireside chat at the Third Annual Stifel CNS Day on Wednesday, April 1, 2021 at 11:30 a.m. ET.

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2020 Results - Earnings Call Transcript

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates

Shares of WAVE Life Sciences (NASDAQ:WVE) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 64.24% year over year to ($0.59), which beat the estimate of ($0.61).

WAVE Life Sciences: Q4 Earnings Insights

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021

Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:00 a.m. ET on Thursday, March 4, 2021, to discuss its fourth quarter and full year 2020 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

Will Wave Life Sciences (WVE) Report Negative Q4 Earnings? What You Should Know

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 p.m. ET.

News for Wave Life Sciences Stock (WVE)